Eptifibatide is a medicine used to prevent blood clots in people who have had a heart attack or are having certain heart procedures. It works by stopping platelets from sticking together, which helps prevent dangerous clots from forming.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Eptifibatide is an intravenous (IV) medicine that stops platelets, the blood cells that start clots, from clumping together. It is given only in the hospital, during treatment for certain heart attacks and around procedures to open blocked heart arteries. It was first sold in the US under the brand name Integrilin, which has since been discontinued; generic eptifibatide is used today. It is approved for two situations. The first is acute coronary syndrome of the unstable angina or NSTEMI type. Unstable angina is chest pain from reduced blood flow to the heart that comes on at rest or is getting worse quickly. NSTEMI (non-ST-elevation myocardial infarction) is a heart attack in which blood tests show heart muscle damage but the heart tracing (ECG) does not show ST elevation, the pattern that usually signals a fully blocked artery. In these patients, whether treated with medicines alone or with a procedure, eptifibatide lowered the combined rate of death or a new heart attack in clinical trials. The second is percutaneous coronary intervention (PCI), in which a thin tube is threaded from the wrist or groin to the heart so a balloon and usually a stent can open a narrowed artery. Here it lowered the combined rate of death, a new heart attack or the need for an urgent repeat procedure. Because it also adds bleeding, cardiologists use it selectively, for people whose clot risk outweighs their bleeding risk, rather than for everyone who has a stent placed.
When the lining of a heart artery is damaged, platelets stick to the spot and then bind to one another to build a clot. To link together, platelets use a receptor on their surface called glycoprotein IIb/IIIa, which grabs proteins in the blood such as fibrinogen that act as bridges between neighboring platelets. Eptifibatide blocks this receptor, so platelets cannot link up even when they have been activated. That keeps a clot from forming or growing in a narrowed artery or on a newly placed stent. The effect begins as soon as the first dose goes in. It is also reversible: once the drip is stopped, the drug comes off the platelets, and most of their clumping ability returns within a few hours. That short action lets the team switch the protection off fairly quickly if bleeding occurs or surgery is needed.
Eptifibatide is given entirely by the hospital team. Treatment starts with a quick injection (a bolus) into a vein, followed right away by a continuous IV drip. People having PCI receive a second bolus about 10 minutes after the first. The dose is calculated from body weight, and the drip rate is lowered for people whose kidney function is reduced. Before starting, the team checks blood counts, platelet count, kidney function and clotting tests to look for problems that would make bleeding more likely. Eptifibatide is normally given together with heparin, an injectable blood thinner, and daily aspirin. The drip usually runs for up to about three days in people managed with medicines alone. After PCI it generally continues for 18 to 24 hours or until discharge, whichever comes first. It is stopped before bypass surgery. Because the treatment is weight-based and closely monitored, there is nothing for a patient to adjust. What helps is giving an accurate weight and making sure the team knows about every blood thinner, recent bleed, stroke or surgery.
Bleeding is the most common problem. It happens most often where the catheter entered the artery in the groin or wrist, and less often from the stomach or bowel, the urinary tract or the gums. Most of it is minor, such as oozing or bruising around the puncture site, but some people need a transfusion. Bleeding risk is higher in older adults, in people who weigh less (particularly under about 70 kg, or 154 pounds) and in people who have had bleeding problems before. Low blood pressure is the other common effect and can cause lightheadedness. Less often, eptifibatide causes a sudden, severe drop in platelets, which is one reason platelet counts are checked during treatment; if it happens, eptifibatide and heparin are stopped. Bleeding inside the skull and allergic reactions, including anaphylaxis, are rare. While the drip is running, tell the nurse right away about new bleeding, swelling or pain at the catheter site, blood in the urine or stool, bleeding gums or a nosebleed, or feeling faint. Staff can then hold pressure on the site and stop the infusion if bleeding cannot be controlled.
Eptifibatide is not given to people whose bleeding risk is clearly too high. That includes abnormal bleeding within the past 30 days or a known bleeding disorder, a stroke in the past 30 days or any past stroke caused by bleeding in the brain, and major surgery in the past six weeks. It is also avoided when blood pressure stays dangerously high despite treatment, meaning a top (systolic) number above 200 or a bottom (diastolic) number above 110, and in people who depend on dialysis. Most of its interactions come from adding one bleeding risk to another. Heparin and aspirin are part of the usual plan, so the team monitors clotting tests closely. Bleeding risk rises further with other antiplatelet medicines such as clopidogrel or ticagrelor, oral blood thinners such as warfarin or apixaban, clot-dissolving drugs and regular use of anti-inflammatory pain relievers such as ibuprofen or naproxen. It is not combined with another IV medicine of the same class, and it is stopped if clot-dissolving treatment becomes necessary. There is too little data to define a risk in pregnancy, and animal studies showed no harm. Because a heart attack in pregnancy can be fatal to both mother and baby, the label says treatment should not be withheld because of concern about the fetus. It is not known whether eptifibatide enters breast milk, but as a protein-like molecule it is likely broken down in a baby's digestive tract.
Eptifibatide is part of a hospital stay, usually on a cardiac unit with heart monitoring. Expect frequent checks of blood pressure, the catheter site and blood tests such as platelet count and hemoglobin. After PCI, the team works to remove the tube (sheath) from the artery and make sure the site has stopped bleeding, with both heparin and eptifibatide off for at least a few hours before discharge. Eptifibatide is not a take-home medicine. Its effect fades within hours after the drip ends, and longer-term protection after a heart attack or stent comes from the oral medicines, such as daily aspirin, that the cardiology team prescribes for discharge. Some bruising at the puncture site is common; bleeding that restarts or a growing, painful swelling there after going home is a reason to contact the care team.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Eptifibatide, what you've noticed, or ask the community a question.